DPP-4 inhibitors may be useful in patients with NAFLD and chronic liver disease, but the patients must be monitored for cirrhotic decompensation and hepatic failure in patients with liver cirrhosis (Figure 1). This evidence concerns the gene DPP4 and liver failure.